Compare Heron Therapeutics Inc (HRTX) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Lufax Holding Ltd — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Lufax Holding Ltd trades at $0.96 (market cap $1.01B). The key difference: Lufax Holding Ltd is far larger — about 13.6× Heron Therapeutics Inc's market cap, and Lufax Holding Ltd is more actively traded (4,754,976 versus 3,668,095). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Lufax Holding Ltd for 13 Days on average.
| HRTX | LU | |
|---|---|---|
Market Cap | $74.04M | $1.01B |
Volume | 3,668,095 | 4,754,976 |
Sector | Health | Financials |
52-Week High | $1.49 | $3.93 |
52-Week Low | $0.27 | $0.95 |
Typical Hold Time | 35 Days | 13 Days |
Enterprise Value | $180.78M | $59.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
LU trades at $0.98, down 2.83% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported a net loss of $2.10 billion on $23.11 billion revenue in 2025, with negative profit margins and declining revenue trends. Recent corporate actions include a 10:1 reverse stock split effective October 2026. Analyst consensus remains predominantly bullish with 69% buy ratings, citing deep value potential despite ongoing operational challenges.
LU presents a high-risk, event-driven opportunity with significant valuation discounts (P/S 0.26, P/B 0.07) but faces substantial execution risks amid regulatory pressures and persistent losses. The stock's outlook hinges on successful restructuring and potential Hong Kong listing catalysts, though near-term headwinds from China's consumer lending sector remain challenging for profitability recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
